Sign In   Register
1 minute reading time (146 words)

Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities

's () Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue generating partnering opportunities for its NanoCelle® drug delivery platform which he says can improve the efficacy of multiple medicines and therapeutics.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE
Heritage Cannabis to bring its brands to Quebec fo...
Australis Capital says Audacious Brands gets footh...

Related Posts


By accepting you will be accessing a service provided by a third-party external to https://www.mjinvest.com/


MjInvest.com